Library Subscription: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Published 6 issues per year

ISSN Print: 0743-4863

ISSN Online: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Liposome-Based Nanomedicine Therapeutics for Rheumatoid Arthritis

Volume 34, Issue 4, 2017, pp. 283-316
DOI: 10.1615/CritRevTherDrugCarrierSyst.2017016067
Get accessGet access

ABSTRACT

Rheumatoid arthritis (RA) is a very painful severe autoimmune disease with complex pathology characterized by progressive chronic inflammation, and devastation of the synovium, cartilage, and other joint-associated structures. Significant advances in research in the area of pathophysiology, diagnosis, drug development, and targeted delivery have led to improved RA therapy and better patient compliance. Targeted drug delivery using liposomal nanomedicines significantly alleviate the challenges with conventional anti-RA medications such as off-target effects, short biological half-life, poor bioavailability, high dose-related toxicity, etc. Liposomal nanomedicines in RA drug targeting offer the opportunity for passive targeting [based on size and polyethylene glycol (PEG)-ylation-mediated enhanced permeability and retention] and active targeting (ligation with antibody or peptides, etc.) and encapsulation of lipophilic, hydrophilic drugs, and/or combinational drugs. However, it has been found recently that such injectable nanomedicines raise the concern of an adverse immune phenomenon called complement activationrelated pseudo allergy (CARPA) and failure of therapy on multiple doses due to accelerated body clearance caused many by anti-PEG immunoglobulin M. To ensure safety and efficacy of RA therapy, these need to be considered along with the common formulation quality parameters. Here, we discuss nanotherapeutic targeting in RA therapy using liposomes. Liposomal nanoparticles are investigated for individual anti-RA drug categories. CARPA issues and pathophysiology with such nanomedicines are also discussed in detail.

CITED BY
  1. Knauer Nadezhda, Pashkina Ekaterina, Apartsin Evgeny, Topological Aspects of the Design of Nanocarriers for Therapeutic Peptides and Proteins, Pharmaceutics, 11, 2, 2019. Crossref

  2. Chavan Tejashri, Muttil Pavan, Kunda Nitesh K., Introduction to Nanomedicine in Drug Delivery, in Mucosal Delivery of Drugs and Biologics in Nanoparticles, 41, 2020. Crossref

  3. Sehnert Bettina, Burkhardt Harald, Dübel Stefan, Voll Reinhard E., Cell-Type Targeted NF-kappaB Inhibition for the Treatment of Inflammatory Diseases, Cells, 9, 7, 2020. Crossref

  4. Song Yanqin, Ismail Muhammad, Shan Qi, Zhao Jianing, Zhu Yanping, Zhang Leiming, Du Yuan, Ling Longbing, ROS-mediated liposomal dexamethasone: a new FA-targeted nanoformulation to combat rheumatoid arthritis via inhibiting iRhom2/TNF-α/BAFF pathways, Nanoscale, 13, 47, 2021. Crossref

  5. Tu Allen B., Lewis Jamal S., Biomaterial-based immunotherapeutic strategies for rheumatoid arthritis, Drug Delivery and Translational Research, 11, 6, 2021. Crossref

  6. Abdellatif Ahmed A. H., Mohammed Hamdoon A., Khan Riaz A., Singh Varsha, Bouazzaoui Abdellatif, Yusuf Mohammad, Akhtar Naseem, Khan Maria, Al-Subaiyel Amal, Mohammed Salman A. A., Al-Omar Mohsen S., Nano-scale delivery: A comprehensive review of nano-structured devices, preparative techniques, site-specificity designs, biomedical applications, commercial products, and references to safety, cellular uptake, and organ toxicity, Nanotechnology Reviews, 10, 1, 2021. Crossref

  7. Guo Rui-bo, Zhang Xin-yue, Yan De-kang, Yu Ying-jie, Wang Yu-jia, Geng Hong-xia, Wu Ya-nan, Liu Yang, Kong Liang, Li Xue-tao, Folate-modified triptolide liposomes target activated macrophages for safe rheumatoid arthritis therapy, Biomaterials Science, 10, 2, 2022. Crossref

  8. Ramalingam Prakash, Prabakaran D. S., Sivalingam Kalaiselvi, Nallal V. Uma Maheshwari, Razia M., Patel Mayurkumar, Kanekar Tanvi, Krishnamoorthy Dineshkumar, Recent Advances in Nanomaterials-Based Drug Delivery System for Cancer Treatment, in Emerging Nanomaterials for Advanced Technologies, 2022. Crossref

  9. Ma Luoyang, Zheng Xiaoyan, Lin Rui, Sun Antonia RuJia, Song Jintong, Ye Zhiqiang, Liang Dahong, Zhang Min, Tian Jia, Zhou Xin, Cui Liao, Liu Yuyu, Liu Yanzhi, Knee Osteoarthritis Therapy: Recent Advances in Intra-Articular Drug Delivery Systems, Drug Design, Development and Therapy, Volume 16, 2022. Crossref

Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain